One less-publicized provision of the Inflation Reduction Act (IRA) enacts a five-year boost in Medicare Part B reimbursement for biosimilar drugs (also known as follow-on biologics or subsequent entry biologics). The reimbursement enhancement is meant to overcome financial disincentives to biosimilar adoption.
In this white paper, Certara’s U.S. market access experts present original research that examines the legislation’s impact on the uptake of biosimilars to date and forecast what’s in store over the final years of the initiative, as a wave of new biosimilars enter the market.
Complete the form to download a free copy of the IRA Biosimilars Outlook 2024 Report
The research delves into the IRA’s “small but measurable” impact and offers insights in several key areas, such as:
- The relationship between awareness of IRA enhanced Medicare part B reimbursement and utilization of biosimilars at oncology treatment sites
- Facility characteristics associated with level of biosimilar utilization
- Relationship between eligibility for the IRA biosimilar reimbursement boost and uptake
- Drivers of and impediments to biosimilar uptake
- Trends in oncology biosimilar uptake and market share
If you’re interested in discussing this topic or other U.S. access trends with our experts, you can contact them directly.
Authors
Caitlin Verrilli, MBA, Director, US Access Strategy
caitlin.verrilli@certara.com
Max Vargas, PhD, MBA, Vice President, US Access Strategy
maximilian.vargas@certara.com
Matias Junghahn, Senior Analyst
matias.junghahn@certara.com
